Page 164 - Demo

168 PROCEEDINGS OF INTERNATIONAL SCIENTIFIC CONFERENCE ON APPLIED BIOTECHNOLOGYindomethacin 10 mg/kgP at 5 hours after carrageenan injection (p<0.05) but equivalent to that of indomethacin 10 mg/kgP at 6 and 7 hours after carrageenan injection (p>0.05). In general, the nanofibers-EPMC 15% showed little better effect than free EPMC althought the content of EPMC in the nanofibers was only 15% of free EPMC. This might be due to the encapsulation of EPMC in nanofibers helped to achieve controlled release and thus increased the efficacy in vivo. The presence of chitosan, an antiinflammatory amino polysaccharide in the nanofibers was also considered to contribute to the anti-inflammatory property of the nanofibers-EPMC 15%. The obtained results showed the potential application of the electrospun nanofibers loaed with 15% EPMC in anti-inflammatory products for the treatment of inflammatory diseases, especially arthritis.5. CONCLUSIONSIn the current paper, we evaluated the in vivo antiinflammatory effects of the nanofibers composed of three polymer including CS, PLA, and PEG carrying EPMC 15% and compared its effect with that of free EPMC through two animal models such as formalin and carrageenan-induced mouse paw edema. The results showed that the nanofibers-EPMC 15% exhibited anti-inflammatory activities by topical and oral routes. In general, the activity of the nanofibers was little better than that of free EPMC although the EPMC content in the fiber was only 15%. The reason was thought to be due to the encapsulation of the active ingredient in the nanostructure, which helped the active ingredient to be released better. Besides, the presence of chitosan polymer, an anti-inflammatory agent, was also considered to contribute to the anti-inflammatory effects of the nanofibers. These findings suggested the application of nanofibers-EPMC 15% to produce anti-inflammatory products in the future.